Fractyl Health Inc. (GUTS) just released some intriguing data that could address one of the biggest problems with GLP-1 weight loss drugs: what happens when you stop taking them?
On Tuesday, the company shared 6-month results from its REVEAL-1 study, which tracked obese patients who had successfully lost at least 15% of their body weight on GLP-1 medications but then needed or chose to discontinue treatment. The findings suggest that a single Revita procedure helped these patients maintain both their weight loss and blood sugar control for six months after stopping their GLP-1 therapy.
What's Actually Happening Here
The Revita procedure isn't your typical weight loss intervention. It uses hydrothermal ablation to essentially remodel the lining of your duodenum—the first part of your small intestine. The theory is that chronic exposure to high-fat and high-sugar diets damages the intestine's nutrient-sensing and signaling mechanisms, and resurfacing that tissue could help restore normal metabolic function.
The Numbers Worth Knowing
Study participants had lost an impressive 24% of their total body weight (more than 50 pounds) while on GLP-1 drugs, having taken them anywhere from 5 months to 5 years. After undergoing the Revita procedure and stopping their medications, these patients showed a mean body weight change of just 1.5% ± 1.3% at the 6-month mark—basically holding steady.
The blood sugar story is equally compelling. Participants saw minimal change in HbA1c levels (0.04% ± 0.08%) after the procedure, compared to the roughly 0.4% increase typically seen when people stop GLP-1 drugs, as documented in the STEP-1 trial extension.
Safety Profile
The procedure appears relatively safe based on this early data. No serious adverse events were linked to the procedure itself. About 36% of participants (8 of 22) experienced mild side effects that resolved on their own—similar to what you'd expect from a routine upper endoscopy.
The average ablation length was approximately 16 centimeters, consistent with real-world experience in Europe and the company's ongoing REMAIN-1 pivotal study, suggesting the technique is reproducible and scalable.
Fractyl Health shares were trading down 4.81% at $1.48 following the announcement.
